Clinical Trial Update: First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene [Phase 2]

View source ↗

Summary

This document reports a Phase 2 clinical trial evaluating first-line EGFR tyrosine kinase inhibition in patients with non-small cell lung cancer harboring EGFR …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma Bronchiolo-alveolar
• Lung Neoplasms
• Non-small Cell Lung Cancer

Snippet

Sponsor: Universitair Ziekenhuis Brussel | Conditions: Lung Neoplasms, Non-Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN